The oncology assay is the first from Roche using either plasma or tumor tissue samples and identifies 42 mutations in the EGFR gene.
The company continues to build evidence for the added sensitivity offered by its urine- and blood-based liquid biopsy approach in an effort to engage clinicians.
A new study suggests that EGFR and MAPK protein abundance is the same across cell lines, while the adaptor proteins vary in number.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.
Genentech's Alecensa and AstraZeneca's Tegrisso are the latest precision lung cancer drugs, and Xalkori might soon be an option for a new molecular subpopulation.
Researchers from a SU2C-sponsored study compared tissue biopsy and liquid biopsy for detecting the T790M mutation of the EGFR gene in a cohort of NSCLC patients.
The preliminary results showed that 76 percent of study subjects under 40 had druggable mutations.
In developing the recommendations, the expert panel attempted to keep up with the fast-moving advances in oncology.
Roche's Cobas EGFR v2 mutation test will be able to identify advanced NSCLC patients with EGFR mutations who are likely to benefit from the next-generation treatment.
Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.
The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.
The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.
Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.
In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.